Drug safety has attracted much attention, and quality supervision and sampling inspections are becoming more frequent

[Pharmaceutical Network Industry News] Recently, the State Food and Drug Administration issued an announcement on the quality of drug sampling inspection.
This sampling inspection involved a total of 20 batches of drugs produced by 9 companies.
It is worth noting that there are 2 batches of injections with visible foreign bodies that do not meet the regulations, 3 Banned pesticide residues were detected in batches of chrysanthemums, and seven batches of comfrey did not meet the regulations.
Risk control measures such as suspension of sales and recalls have been taken for the above-mentioned drugs
.

Medicines are special commodities and are closely related to human health and safety
.

In order to ensure the safety of people's medication, the state's supervision over the product quality of pharmaceutical companies has been continuously increasing
.

Since the beginning of this year, the State Food and Drug Administration has actually issued several announcements on drug quality sampling, and a large number of drugs have been suspended and recalled
.

In this regard, the industry believes that this fully reflects that the state is still implementing strict supervision over drugs
.

It is understood that since the beginning of this year, in order to strengthen the supervision of drug quality and ensure the safety of public medication, many places have also launched supervision and inspection of drug production, operation, and use units, and issued announcements
.

For example, on June 20, the Chongqing Municipal Drug Administration website also issued a notice about 9 batches of drugs that did not meet the regulations
.

According to the notice, 9 batches of medicines such as whole scorpion, ginkgo biloba, safflower, and red ginseng tablets produced by enterprises such as Henan Shanghuatang Pharmaceutical Co.
compliant
.

For the above products that do not meet the requirements, the Chongqing Municipal Drug Administration has instructed the relevant inspection bureaus and the district and county drug regulatory departments to take necessary control measures such as sealing up, seizure, suspension of sales, recall, etc.
, and investigate and deal with them in accordance with relevant laws and regulations
.

 　　On April 6, the Fujian Provincial Food and Drug Administration issued a notice on the results of the first phase of drug quality random inspection in 2022
.

After sorting out, it was found that 4 batches of drugs from 4 drug manufacturers were found to be unqualified this time.

.

The unqualified drugs included three pieces of Chinese herbal medicines: Schisandra chinensis, Haijinsha, and rose; and one western medicine: oxytetracycline tablets
.

For the above-mentioned products and enterprises that fail to pass the random inspection, the Fujian Provincial Food and Drug Administration has organized inspections and disposals in accordance with the law, and the suspected illegal enterprises have been investigated and dealt with in accordance with the law
.

 　　Since the beginning of this year, the Feixi County Market Supervision Bureau has also carried out a comprehensive sampling inspection of drug business enterprises in the county according to the 2022 drug sampling inspection work arrangement
.

So far, the county market supervision bureau has sampled 51 batches of drugs, including 26 batches of essential drugs and high-risk drugs, and 25 batches of daily supervision and sampling, and the samples are sealed and submitted for inspection according to the procedures
.

It is understood that in the next step, the bureau will continue to carry out drug sampling inspections and do a good job in tracking and disposing of unqualified drugs.
Guided by the problems found in the sampling inspections, it will continue to maintain a high-pressure drug supervision situation, build a strong drug safety line of defense, and ensure public medication.
Safe
.

 　　Frequent sampling inspections mean that the safety of drugs has become the focus of attention in the industry
.

In order to strengthen drug quality supervision and ensure the safety of public medication, the state and relevant departments in various regions will continue to strengthen drug quality supervision and sampling
.

In fact, on June 22, the General Office of the National Health and Health Commission issued a notice on printing and distributing the 2022 national random supervision and inspection plan
.

In order to further strengthen the supervision and law enforcement of public health, medical care, etc.
, in accordance with the State Council's work deployment on "double randomization, one disclosure" and the relevant requirements of key health work in 2022, the National Health Commission has organized and formulated the 2022 national random supervision and random inspection plan
.

 　　The contents of supervision and spot checks include: vaccination management in medical and health institutions, focusing on inspection of the reception, storage, and vaccination of new coronavirus vaccines; epidemic reporting of infectious diseases in medical and health institutions, epidemic control, implementation of disinfection and isolation measures, medical waste management, and pathogenic microbiology laboratories Biosecurity management,
etc.

 　　In this context, for pharmaceutical companies, it is necessary to pay more attention to strictly abide by regulations and control the production quality of each link; at the same time, through continuous innovation and improvement of the system, to further enhance the competitiveness of products and control the challenges of drug safety risks ability and level
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.